Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSE:4570'
s EV-to-FCF Range Over the Past 10 Years
Min: -44.92 Med: -6.8 Max: 270.43
Current: 31.76
During the past 13 years, the highest EV-to-FCF of Immuno-Biological Laboratories Co was 270.43. The lowest was -44.92. And the median was -6.80.
TSE:4570's EV-to-FCF is ranked worse than 68.06% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs TSE:4570: 31.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Immuno-Biological Laboratories Co (TSE:4570) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Immuno-Biological Laboratories Co's PE Ratio (TTM) for today is calculated as:
Immuno-Biological Laboratories Co's share price for today is 円994.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immuno-Biological Laboratories Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円35.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Immuno-Biological Laboratories Co EV-to-FCF Related Terms
Immuno-Biological Laboratories Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4570 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Immuno-Biological Laboratories Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuno-Biological Laboratories Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Immuno-Biological Laboratories Co's EV-to-FCF falls into.
Immuno-Biological Laboratories Co's current Enterprise Value is 円8,445 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immuno-Biological Laboratories Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円268 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuno-Biological Laboratories Co (TSE:4570) has a EV-to-FCF of 31.55 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Immuno-Biological Laboratories Co and its competitors. According to the industry distribution chart, Immuno-Biological Laboratories Co ranks #228 out of 335 companies in the Biotechnology industry, placing it in the top 68.1%.
Is Immuno-Biological Laboratories Co's EV-to-FCF too high?
Immuno-Biological Laboratories Co's current EV-to-FCF is 31.55. The Biotechnology industry median EV-to-FCF is 15.34. Immuno-Biological Laboratories Co's value of 31.55 is 105.7% above this industry median. Based on the distribution chart, Immuno-Biological Laboratories Co ranks #228 out of 335 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuno-Biological Laboratories Co ranks #228 out of 335 companies for EV-to-FCF. This places Immuno-Biological Laboratories Co in the lower half of its industry. The industry median EV-to-FCF is 15.34. Immuno-Biological Laboratories Co's value of 31.55 is 105.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuno-Biological Laboratories Co's current EV-to-FCF of 31.55 is 105.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Immuno-Biological Laboratories Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuno-Biological Laboratories Co's current EV-to-FCF is 31.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円578.92, compared to a current price of 円994.00 — trading 71.7% above its estimated fair value. The current EV-to-FCF is 31.55 and 105.7% above the Biotechnology industry median of 15.34. Immuno-Biological Laboratories Co's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current EV-to-FCF is 31.55 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued.
The current stock price of 円994.00 is trading 71.7% above its estimated GF Value™ of 円578.92.
GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.
Key valuation signals for TSE:4570:
EV-to-FCF: 31.55
GF Value™: 円578.92 vs. price of 円994.00 (71.7% above fair value)
Industry Position: 105.7% above the Biotechnology median (#228 of 335)
No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuno-Biological Laboratories Co Business Description
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
58GF Score
Get the complete analysis for TSE:4570
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4570 has been successfully added to your 
